Koers ReNeuron Group Plc London S.E.
Aandelen
Biotechnologie & Medisch Onderzoek
Omzet 2022 | 403K 503K 471K | Omzet 2023 | 530K 662K 619K | Marktkapitalisatie | 5,17 mln. 6,46 mln. 6,04 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -9 mln. -11,24 mln. -10,51 mln. | Nettowinst (verlies) 2023 | -5 mln. -6,25 mln. -5,84 mln. | EV/omzet 2022 | 8,48 x |
Nettoliquiditeiten 2022 | 13,99 mln. 17,47 mln. 16,33 mln. | Nettoliquiditeiten 2023 | 6,73 mln. 8,41 mln. 7,86 mln. | EV/omzet 2023 | -2,94 x |
K/w-verhouding 2022 |
-1,79
x | K/w-verhouding 2023 |
-0,96
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 78,26% |
Recentste transcriptie over ReNeuron Group Plc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
John Hawkins
DFI | Director of Finance/CFO | 58 | 01-10-14 |
Suzanne Hancock
COO | Chief Operating Officer | - | 01-01-17 |
Chief Tech/Sci/R&D Officer | - | 03-03-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Martin Walton
BRD | Director/Board Member | 61 | 22-03-22 |
Iain Ross
CHM | Chairman | 71 | 01-07-21 |
Director/Board Member | 61 | 14-07-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,51% | 42,75 mld. | |
+49,22% | 41,61 mld. | |
+8,57% | 41,34 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |